David A. Siegel Humacyte, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Humacyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 147,100 shares of HUMA stock, worth $486,901. This represents 0.0% of its overall portfolio holdings.
Number of Shares
147,100
Previous 188,400
21.92%
Holding current value
$486,901
Previous $1.02 Million
27.54%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding HUMA
# of Institutions
172Shares Held
41MCall Options Held
553KPut Options Held
942K-
Black Rock Inc. New York, NY7.14MShares$23.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$18.5 Million0.0% of portfolio
-
State Street Corp Boston, MA4.61MShares$15.3 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.85MShares$9.43 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA2.14MShares$7.07 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $341M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...